4 documents found, page 1 of 1
Safety, Efficacy and Pharmacokinetics of daily optimised doses of Rifampicin fo...
Espinosa-Pereiro, J; Aguiar, A; Nara, E; Medina, A; Molinas, G; Tavares, M; Tortola, T; Ghimire, S; Alfenaar, JC; Sturkenboom, MGG; Magis-Escurra, C"Background: Higher than standard doses of rifampicin could improve the treatment outcome of drug-susceptible tuberculosis without compromising the safety of patients. Methods: We performed a systematic review of prospective clinical studies including adults with pulmonary and extrapulmonary TB receiving rifampicin doses above 10mg/kg/day. We extracted the data on overall adverse events (AE), hepatic AE, sputum...
Long-term outcomes of the global tuberculosis and COVID-19 co-infection cohort
Casco, N; Jorge, AL; Palmero, DJ; Alffenaar, JW; Fox, GJ; Ezz, W; Cho, JG; Denholm, J; Skrahina, A; Solodovnikova, V; Arbex, MA; Alves, T; Rabahi, MFBackground Longitudinal cohort data of patients with tuberculosis (TB) and coronavirus disease 2019 (COVID-19) are lacking. In our global study, we describe long-term outcomes of patients affected by TB and COVID-19. Methods We collected data from 174 centres in 31 countries on all patients affected by COVID-19 and TB between 1 March 2020 and 30 September 2022. Patients were followed-up until cure, death or end...
Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis ...
Sánchez van Kammen, M; Aguiar de Sousa, D; Poli, S; Cordonnier, C; Heldner, M; van de Munckhof, A; Krzywicka, K; van Haaps, T; Ciccone, A; Middeldorp, SImportance: Thrombosis with thrombocytopenia syndrome (TTS) has been reported after vaccination with the SARS-CoV-2 vaccines ChAdOx1 nCov-19 (Oxford-AstraZeneca) and Ad26.COV2.S (Janssen/Johnson & Johnson). Objective: To describe the clinical characteristics and outcome of patients with cerebral venous sinus thrombosis (CVST) after SARS-CoV-2 vaccination with and without TTS. Design, setting, and participants: ...
Predicting non-invasive ventilation failure in children from the SpO₂/FiO₂ (SF)...
Mayordomo-Colunga, J; Pons, M; López, Y; Solana, MJ; Rey, C; Martı´nez-Camblor, P; Rodríguez-Núñez, A; López-Herce, J; Medina, A; Abadesso, CPURPOSE: Our objective was to assess whether SpO₂/FiO₂ (SF) ratio could be a useful NIV outcome predictor in children with acute respiratory failure (ARF) and tried to develop a predictive model of NIV failure. METHODS: Prospective, observational, multicenter study. Episodes of ARF-fulfilling inclusion criteria from 15 January 2010 to 14 January 2011 were treated with NIV according to a pre-established protocol...